pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
00948b32-d1ab-4721-a4a0-83523d3b0454
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-17 14:41:12
Income (reported)
$60,000
Expenses (reported)
Filing document
Open on lda.senate.gov

Registrant (lobbying firm)

LMH STRATEGIC SOLUTIONS

Contact
ALANNA TEMME
Phone
+1 202-503-5189
Address
zip:20007, city:Washington, state:DC, street:2231 48th Street NW

Client

SAVARA INC.

Biopharmaceutical company focused on rare respiratory diseases.

State
PA
Country
US
Effective date
2025-10-01

Issues lobbied + lobbyists

PHA — Pharmacy

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

Lobbyists: ALANNA TEMME (covered position: Legislative Director, U.S. Representative Jon Porter); SOPHIE KHANAHMADI (covered position: Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions); MAXIMILIAN WALTER

Government entities lobbied: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

HCR — Health Issues

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.

Lobbyists: ALANNA TEMME; SOPHIE KHANAHMADI; MAXIMILIAN WALTER

Government entities lobbied: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.

Estimated value: $180/mo per user — but we made it free.